转录辅助选择 (TAS) 的作物疾病耐药性:战略和证据
Jiu Huang1, Guangxun Qi2, Mei Li1
1Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 100081, China.
International journal of molecular sciences
|November 27, 2024
概括
一种新的转录辅助选择 (TAS) 策略使用植物免疫基因来识别抗病作物. 这种方法准确地预测了对大豆菌的耐药性,为改善作物提供了一个有前途的工具.
科学领域:
- 植物病理学 植物病理学
- 分子生物学分子生物学
- 农业科学 农业科学
背景情况:
- 植物免疫路径,特别是酸 (SA) 介导的信号传递,在病原体攻击时涉及差异表达基因 (DEG).
- 了解这些分子机制对于开发提高作物抗病能力的策略至关重要.
研究的目的:
- 提出和验证一种转录辅助选择 (TAS) 策略,用于选具有高抗病能力的作物.
- 在植物免疫路径中识别和利用特定的DEG作为疾病耐药性的标志物.
主要方法:
- 该研究的重点是SA信号通路,并确定了转录检测的目标DEG.
- 反转录聚合酶链反应 (RT-PCR) 用于根据基因表达水平选大豆生殖质.
- 通过对*Peronospora manshurica* (Pm) 进行接种,进一步验证了选定的大豆系.
主要成果:
- 在*GmSAGT1*基因表达和大豆菌 (SDM) 耐药性之间观察到高相关性 (R2 = 0.7981).
- 在TAS查中,发现了26种大豆生殖质,其表达高的*GmSAGT1*和*GmPR1*.
- 验证显示TAS预测与实际的*Pm*接种结果之间具有令人满意的一致性 (R2 = 0.7035),几条线表现出高耐药性.
结论:
- 转录辅助选择 (TAS) 策略是选具有增强抗病能力的作物的有效方法.
- TAS促进了具有关键免疫基因高表达的生殖质的选择,与改善的耐药性相关.
- 这种方法有可能开发具有广泛和长期抗病能力的作物.
相关概念视频
Plant Breeding and Biotechnology
18.8K
Crop cultivation has a long history in human civilization, with records showing the cultivation of cereal plants beginning at around 8000 BC. This early plant breeding was developed primarily to provide a steady supply of food.
18.8K
Transgenic Plants
7.2K
Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
7.2K
Transgenic Organisms
30.9K
Overview
30.9K


